r&d
MediGene
MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner.MediGene applies state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases and pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization.
MediGene is the first industrial partner of 
and engaged in a joint project on the development of anti-allergy and anti-cancer vaccines.
Projects
|
Since April 1st, 2010 , the first
At present, immunotherapy against allergies (also called hyposensitization) is still performed with extracts derived from crude allergen sources, such as house dust mite extracts, or extracts from grass pollen. This implies that the patient is not only desensitized against allergens, but also newly exposed to irrelevant compounds of the extract. We aim to avoid this by very specifically applying mimotopes, i.e. small structures that mimic the specific allergen. These mimotopes lead to the production of immunoglobulins blocking the allergic reaction - so-called blocking antibodies. In cancer, immunotherapy is today performed in a passive mode, by supplying the patients´ blood with immunoglobulins against specific molecules of her/his cancer cells. In contrast to these passive immunotherapies, we aim to actively stimulate the patient´s immune system to build up own antibodies. This principle is well known from vaccines against infectious diseases and we are convinced that within a few years, vaccination will be a real option for patients. |
|
